Print Programme

Annual meeting of SFTCG 

ENS, Lyon, France 

11 to 13 March, 2020

Wednesday 11 March

09:00

12:00

Matinée portes ouvertes pour les lycéens de Lyon Speed-searching: Interaction avec les chercheurs et leurs outils de travail

  Session pour les patients et associations de patients
1) Introduction générale sur la thérapie génique
2) Atelier individuel sur différents thèmes
3) Table Rond introduit par un film
13:30  Registration
14:00 

Opening Keynote
Chair: François-Loïc Cosset, Els Verhoeyen
INV01  Fulvio Mavilio,  Audentes Therapeutics, San Francisco
Gene therapy of inherited muscle diseases

14:45 15:45

Session 1 : Gene editing in gene therapy
Chair: François-Loïc Cosset, François Moreau-Gaudry 

INV02  Claudio Mussolino, Freiburg University
Advances in precision genome and epigenome editing for human gene therapy
INV03  Fernando Larcher, Ciemat / Ciberer, Madrid
CRISPR/Cas9-based gene editing strategies for clinically-relevant ex vivo correction of Recessive Dystrophic Epidermolysis Bullosa
INV04  Annarita Miccio, Imagen, Paris
CRISPR/Cas9-based therapeutic strategies for β-hemoglobinopathies

2 selected abstracts

15:45 

16:15 

Coffee break

16:15

18:15 

Session 2 : In vivo gene therapy
Chair: Eduard Ayuso, Capucine Trollet

INV05  Gloria Aseguinolaza,   CIMA, Pamplona
Gene therapy for inherited liver diseases
INV06  Martina Marinello, Geneton, Evry
Gene therapy of spinal muscular atrophy by single-stranded AAV9 vectors
INV07  Fred Thalheimer,  Paul Elrich Institute, Langen
In vivo
generation of functional CAR T cells selectively in human CD4+ lymphocytes

2 selected abstracts

SFTCG General Assembly

18:30 

Welcome reception and Posters

 
Thursday 12 March

9:00

11:00

Session 3: Innovative approaches
Chairs: Michel Pucéat, Els Verhoeyen

INV11 Tuan Nguyen, Golliver Therapeutics, Nantes 
Pluripotent stem cell-based ATMPs for liver repair
INV12 Jens Schwamborn, University of Luxemburg
Human midbrain organoids for Parkinson`s disease in vitro modeling and drug development in
INV13 Valérie Dardalhon, IGMM, Montpellier 
Targeting the metabolic environment to modulate CAR-T cell effector function

2 selected abstracts

11:00

11:30

Coffee Break

11:30

13:30

Session 4: Cancer gene therapy
Chair: Nicolas Boisgerault, Pierre Cordelier

INV14 Andrea Biondi, University of Milano Bicocca, Monza 
TBC
INV15 Nicolas Ferry, Servier
CAR-T cells, the slow road from autologous to allogenic origin
INV16 Yaohe Wang, Barts Cancer Institute, London
TBC

2 selected abstracts

13:30

15:00

Lunch and Posters

15:00

17:00

Session 5 : Stem Cells and iPS
Chair: John De Vos, Leila Maouche-Chrétien

INV08 Guillaume Rousseau, EryPharm, Paris  
Ex vivo production of Red Blood Cells from stem cells for transfusion purposes
INV09 Pierre Savatier, Stem Cell and Brain Research Institute, Lyon
Naive-state pluripotency and chimeric competency in human and non-human primates
INV10 Christelle Monville, Istem, Evry 
Retinal Pigment Epithelial cells derived from human embryonic stem cells disposed on human amniotic membrane: An update on the French RP clinical trial

2 selected abstracts

17:00

17:30

Coffee Break

17:30

19:30

Session 6: Towards clinical trials
Chair: Anne Galy, Nathalie Cartier

INV17 Françoise Piguet, Inserm, Paris
Restoring neuronal cholesterol metabolism in ALS mouse model
INV18 Matthias Titeux, Institut Imagine, Paris
TBC
INV19 Magda Papadaki, Merck, London
Understanding and managing regulatory and reimbursement uncertainty during ATMP development: commercial and business impacts

2 selected abstracts

20:00 Congress dinner and party
 
Friday 13 March

09:30

11:30

Session 7: Clinical trials & more
Chair: Olivier Nègre, Federico Mingozzi
INV20 Christian Jorgensen, IRMB, Montpellier
Etat des lieux de la thérapie régénératrice  dans la discopathie degenerative
INV21 Michael Hocquemiller, Lysogene
LYS-SAF302 gene therapy study in mucopolysaccharidosis type IIIA (MPS IIIA) children
INV22 Francisco Fernandez Aviles, Hospital General Universitario Gregorio Marañón, Madrid
Cell therapies for cardiac repair: A mechanistic approach

2 selected abstracts

11:30

12:00

Coffee break

12:00

13:00

Closing keynote
Chair: Els Verhoeyen

INV23  Juan Bueren, CIEMAT/Ciberer, Madrid
Gene Therapy in Hematopoietic Stem Cell Diseases: The Fanconi anemia model

Poster and oral presentation awards